Rituximab biosimilar - Inbiopro Solutions

Drug Profile

Rituximab biosimilar - Inbiopro Solutions

Alternative Names: IBPB 001RX

Latest Information Update: 19 Aug 2013

Price : $50

At a glance

  • Originator Inbiopro Solutions
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Aug 2013 No development reported - Clinical-Phase-Unknown for Non-Hodgkin's lymphoma in India (IV)
  • 19 Aug 2013 No development reported - Clinical-Phase-Unknown for Rheumatoid arthritis in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top